Lipoprotein (a) assay methods similarly predict MACE reduction with PCSK9 inhibitor Alirocumab: Study
USA: A recent comparison of changes in lipoprotein(a) mass and molar concentrations found that each essay method is similarly predictive of major adverse cardiovascular events (MACE) reductions with alirocumab (ALI). The study stated, “With caveats of a modest number of MACE for analysis, moderately elevated Lp(a) levels, and intra-patient variability in serial values, three Lp(a) […]